Insiders who reported open-market trades in the last 12 months at the companies Nicholas A. Saccomano files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Jason A. Leverone - $3K in OKUR purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Nicholas A. Saccomano is a corporate insider, tracked as President and CEO, Director of OnKure Therapeutics, Inc. (OKUR). InsiderAlpha holds 7 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Nicholas A. Saccomano submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Nicholas A. Saccomano been buying or selling stock?
Recorded transactions: 0 open-market purchases and 4 open-market sales ($1K) across all tracked filings.
Nicholas A. Saccomano is President and CEO, Director of OnKure Therapeutics, Inc. (OKUR). 7 SEC Form 4 filings on record going back to 2024, most recently on 23 September 2026. Most recent open-market trade: sold $259 of OKUR on 23 September 2026. Lifetime open-market sales: $1K.
Recent transactions
5
The latest 5 SEC Form 4 transactions reported by Nicholas A. Saccomano.
InsiderAlpha's records for Nicholas A. Saccomano go back to 2024: 7 primary Form 4 filings, an average of 2.3 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
